Legal And IP Protection For New Biotechs

By Matthew Pillar, Editor, Bioprocess Online

There’s a reason why some of the best-performing biopharma companies in the world are led by biotech lawyers. From IP and patent protection to navigating the labyrinth of legislative action that impacts biopharma, legal and IP work is an important and full-time job. That’s why, whether you’re a biotech legal scholar or not, I’d love for you to join me on Monday, 11/13 at 11 AM ET for the special Business of Biotech Live interactive digital event, Legal And IP Protection For New Biotechs, featuring BlueSphere Bio CEO Keir LoIacono, Esq.

Keir is a renowned biotech legal expert with experience ranging from general counsel and VP of Corporate Development for Oncosec to lead in-house counsel and senior director for Advaxis and intellectual property attorney at the powerhouse biotech law firm Lerner, David, Littenberg, Krumholz, and Mentlick. He’s ready to share all that experience with you on 11/13.

Keir and I will discuss IP and other legal considerations for new biotech entities—from protecting the novelty of your molecular assets to the impact of legislative action and a whole lot more. We’ll also dedicate LOTS of time for audience Q&A. It’s a great opportunity to network and consult with one of the premier legal minds in the biotech industry, live and from the comfort of your own desk, and without any lawyer’s fees!

Unlike regular episodes of the Business of Biotech podcast, you must register to reserve your spot for this live, interactive digital event. You can do that here.

Looking forward to seeing you there, and as always, if you have any questions feel free to send me email at matt.pillar@lifescienceconnect.com.